Charger SetPoint System
SetPoint Medical · Decision date Oct 16, 2026
What did the FDA decide?
The FDA database entry for supplement S003 to PMA P240039 records an OK30 decision dated 2026-10-16. The statement describes approval for manufacturing changes to the Charger Litz Wire Cleaning method and the printed circuit board assembly (PCBA). The supplement type is a 30-Day Notice, and the stated reason is a process change involving manufacturer, sterilizer, packager, or supplier.
The device category is a vagus nerve stimulator for rheumatoid arthritis, with product code SFJ and applicant SetPoint Medical. The entry does not state what the specific cleaning method change or PCBA change involves, nor does it provide safety or effectiveness data. A supplement is not a new approval of the whole system, and the statement's reported purpose is distinct from independent proof of clinical benefit.
FDA approval order statement
Approval for manufacturing changes to Charger Litz Wire Cleaning method and the printed circuit board assembly (PCBA).
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240039/S003
- Regulatory pathway
- PMA supplement
- Applicant
- SetPoint Medical
- Product code
- SFJ
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Vagus nerve stimulator for rheumatoid arthritis.
- Applicant
- SetPoint Medical
- Product code
- SFJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240039. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240039 · Original PMA
SetPoint System
P240039/S003 received
Application receipt date recorded by FDA.
P240039/S003 · FDA decision
30-Day Notice
P240039/S004 · Related supplement
SetPoint System
Timeline entries are records held by MedtechLedger for P240039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SetPoint SystemP240039 | SetPoint Medical | PMA approval | Jul 30, 2025 | FDA |
SetPoint SystemP240039/S004 | SetPoint Medical | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
SetPoint Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 25101 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P240039/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records